PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

PacBio reported an adjusted loss per share of 14 cents for Q2 2026, meeting estimates, but revenues of $39 million missed expectations and were down 2% year over year. The company reduced its 2026 revenue guidance to $155-$165 million due to weaker instrument sales, funding constraints in the Americas and Asia-Pacific, and slower-than-expected adoption of new chemistry. Despite challenges, PacBio highlighted growth in consumables revenue, strong clinical demand, and increased revenues in EMEA.